These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 30145624

  • 1. Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
    Nardin C, Borot S, Beaudoin MA, Cattin F, Puzenat E, Gauthier AS, Schillo F, Borg C, Aubin F.
    Invest New Drugs; 2019 Apr; 37(2):375-377. PubMed ID: 30145624
    [Abstract] [Full Text] [Related]

  • 2. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
    Earl DE, Loochtan AI, Bedlack RS.
    Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
    [No Abstract] [Full Text] [Related]

  • 3. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
    Woodbeck R, Metelitsa AI, Naert KA.
    Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
    [Abstract] [Full Text] [Related]

  • 4. Lupus-like cutaneous reaction following pembrolizumab: An immune-related adverse event associated with anti-PD-1 therapy.
    Shao K, McGettigan S, Elenitsas R, Chu EY.
    J Cutan Pathol; 2018 Jan; 45(1):74-77. PubMed ID: 29028121
    [Abstract] [Full Text] [Related]

  • 5. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR, Appah E, Yang LV, Muzaffar M, Marie MA, Mccallen JD, Macherla S, Liles D, Walker PR.
    J Immunother Cancer; 2019 Jul 05; 7(1):169. PubMed ID: 31277704
    [Abstract] [Full Text] [Related]

  • 6. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
    Yip RHL, Lee LH, Schaeffer DF, Horst BA, Yang HM.
    Melanoma Res; 2018 Dec 05; 28(6):645-647. PubMed ID: 30256271
    [Abstract] [Full Text] [Related]

  • 7. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
    Blakeway EA, Elshimy N, Muinonen-Martin A, Marples M, Mathew B, Mitra A.
    Melanoma Res; 2019 Jun 05; 29(3):338-341. PubMed ID: 30762712
    [Abstract] [Full Text] [Related]

  • 8. PD-1 inhibitor induced alopecia areata.
    Guidry J, Brown M, Medina T.
    Dermatol Online J; 2018 Dec 15; 24(12):. PubMed ID: 30677804
    [Abstract] [Full Text] [Related]

  • 9. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
    Durães J, Coutinho I, Mariano A, Geraldo A, Macário MC.
    Mult Scler; 2019 Jun 15; 25(7):1005-1008. PubMed ID: 30311534
    [Abstract] [Full Text] [Related]

  • 10. Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
    Möhn N, Sühs KW, Gingele S, Angela Y, Stangel M, Gutzmer R, Satzger I, Skripuletz T.
    Melanoma Res; 2019 Aug 15; 29(4):435-440. PubMed ID: 30855529
    [Abstract] [Full Text] [Related]

  • 11. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
    Nguyen BH, Kuo J, Budiman A, Christie H, Ali S.
    Melanoma Res; 2017 Apr 15; 27(2):152-154. PubMed ID: 27776019
    [Abstract] [Full Text] [Related]

  • 12. Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanoma.
    Parakh S, Nguyen R, Opie JM, Andrews MC.
    Australas J Dermatol; 2017 Aug 15; 58(3):e109-e112. PubMed ID: 27170423
    [Abstract] [Full Text] [Related]

  • 13. A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma.
    Hanna KS.
    Pharmacotherapy; 2016 Nov 15; 36(11):e183-e188. PubMed ID: 27716999
    [Abstract] [Full Text] [Related]

  • 14. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN, Kudinov AE, Dulaimi E, Boumber Y.
    BMC Cancer; 2019 Apr 24; 19(1):379. PubMed ID: 31018834
    [Abstract] [Full Text] [Related]

  • 15. [A case of meningoencephalitis associated with pembrolizumab treated for squamous cell lung cancer].
    Yonenobu Y, Ishijima M, Toyooka K, Fujimura H.
    Rinsho Shinkeigaku; 2019 Feb 23; 59(2):105-108. PubMed ID: 30700688
    [Abstract] [Full Text] [Related]

  • 16. Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab.
    Lederhandler MH, Ho A, Brinster N, Ho RS, Liebman TN, Lo Sicco K.
    J Drugs Dermatol; 2018 Jul 01; 17(7):807-809. PubMed ID: 30005106
    [Abstract] [Full Text] [Related]

  • 17. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y, Kitano S, Tsutsumida A, Namikawa K, Takahashi A, Nakamura Y, Yamanaka T, Yamamoto N, Yamazaki N.
    J Dermatol; 2019 Jun 01; 46(6):498-506. PubMed ID: 30945333
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
    Arianayagam S, Ieremia E, Matin RN.
    Eur J Dermatol; 2019 Jun 01; 29(3):349-351. PubMed ID: 31389799
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.